Literature DB >> 22084114

Modeling rotavirus strain dynamics in developed countries to understand the potential impact of vaccination on genotype distributions.

Virginia E Pitzer1, Manish M Patel, Ben A Lopman, Cécile Viboud, Umesh D Parashar, Bryan T Grenfell.   

Abstract

Understanding how immunity shapes the dynamics of multistrain pathogens is essential in determining the selective pressures imposed by vaccines. There is currently much interest in elucidating the strain dynamics of rotavirus to determine whether vaccination may lead to the replacement of vaccine-type strains. In developed countries, G1P[8] strains constitute the majority of rotavirus infections most years, but occasionally other genotypes dominate for reasons that are not well understood. We developed a mathematical model to examine the interaction of five common rotavirus genotypes. We explored a range of estimates for the relative strength of homotypic vs. heterotypic immunity and compared model predictions against observed genotype patterns from six countries. We then incorporated vaccination in the model to examine its impact on rotavirus incidence and the distribution of strains. Our model can explain the coexistence and cyclical pattern in the distribution of genotypes observed in most developed countries. The predicted frequency of cycling depends on the relative strength of homotypic vs. heterotypic immunity. Vaccination that provides strong protection against G1 and weaker protection against other strains will likely lead to an increase in the relative prevalence of non-G1 strains, whereas a vaccine that provides equally strong immunity against all strains may promote the continued predominance of G1. Overall, however, disease incidence is expected to be substantially reduced under both scenarios and remain below prevaccination levels despite the possible emergence of new strains. Better understanding of homotypic vs. heterotypic immunity, both natural and vaccine-induced, will be critical in predicting the impact of vaccination.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22084114      PMCID: PMC3228484          DOI: 10.1073/pnas.1110507108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  56 in total

1.  Dynamic effects of antibody-dependent enhancement on the fitness of viruses.

Authors:  Derek A T Cummings; Ira B Schwartz; Lora Billings; Leah B Shaw; Donald S Burke
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-10       Impact factor: 11.205

2.  Ecological and immunological determinants of dengue epidemics.

Authors:  Helen J Wearing; Pejman Rohani
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-25       Impact factor: 11.205

3.  The transmission dynamics of groups A and B human respiratory syncytial virus (hRSV) in England & Wales and Finland: seasonality and cross-protection.

Authors:  L J White; M Waris; P A Cane; D J Nokes; G F Medley
Journal:  Epidemiol Infect       Date:  2005-04       Impact factor: 2.451

4.  Modelling the seasonality of rotavirus disease and the impact of vaccination in England and Wales.

Authors:  Christina Atchison; Ben Lopman; William John Edmunds
Journal:  Vaccine       Date:  2010-03-01       Impact factor: 3.641

Review 5.  Rotavirus disease and vaccination: impact on genotype diversity.

Authors:  Jelle Matthijnssens; Joke Bilcke; Max Ciarlet; Vito Martella; Krisztián Bányai; Mustafizur Rahman; Mark Zeller; Philippe Beutels; Pierre Van Damme; Marc Van Ranst
Journal:  Future Microbiol       Date:  2009-12       Impact factor: 3.165

6.  Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok.

Authors:  B Adams; E C Holmes; C Zhang; M P Mammen; S Nimmannitya; S Kalayanarooj; M Boots
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-11       Impact factor: 11.205

Review 7.  Critical issues in dengue vaccine development.

Authors:  Stephen J Thomas; Timothy P Endy
Journal:  Curr Opin Infect Dis       Date:  2011-10       Impact factor: 4.915

Review 8.  Rotavirus vaccines: current prospects and future challenges.

Authors:  Roger I Glass; Umesh D Parashar; Joseph S Bresee; Reina Turcios; Thea K Fischer; Marc-Alain Widdowson; Baoming Jiang; Jon R Gentsch
Journal:  Lancet       Date:  2006-07-22       Impact factor: 79.321

Review 9.  Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine.

Authors:  Norma Santos; Yasutaka Hoshino
Journal:  Rev Med Virol       Date:  2005 Jan-Feb       Impact factor: 6.989

10.  The protective effectiveness of natural rotavirus infection in an American Indian population.

Authors:  L H Moulton; M A Staat; M Santosham; R L Ward
Journal:  J Infect Dis       Date:  1998-12       Impact factor: 5.226

View more
  30 in total

1.  Vacated niches, competitive release and the community ecology of pathogen eradication.

Authors:  James O Lloyd-Smith
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-06-24       Impact factor: 6.237

2.  Multiple Introductions and Antigenic Mismatch with Vaccines May Contribute to Increased Predominance of G12P[8] Rotaviruses in the United States.

Authors:  Kristen M Ogden; Yi Tan; Asmik Akopov; Laura S Stewart; Rendie McHenry; Christopher J Fonnesbeck; Bhinnata Piya; Maximilian H Carter; Nadia B Fedorova; Rebecca A Halpin; Meghan H Shilts; Kathryn M Edwards; Daniel C Payne; Mathew D Esona; Slavica Mijatovic-Rustempasic; James D Chappell; John T Patton; Natasha B Halasa; Suman R Das
Journal:  J Virol       Date:  2018-12-10       Impact factor: 5.103

Review 3.  Models to predict the public health impact of vaccine resistance: A systematic review.

Authors:  Molly C Reid; Kathryn Peebles; Sarah E Stansfield; Steven M Goodreau; Neil Abernethy; Geoffrey S Gottlieb; John E Mittler; Joshua T Herbeck
Journal:  Vaccine       Date:  2019-07-12       Impact factor: 3.641

4.  Diversity and relationships of cocirculating modern human rotaviruses revealed using large-scale comparative genomics.

Authors:  Sarah M McDonald; Allison O McKell; Christine M Rippinger; John K McAllen; Asmik Akopov; Ewen F Kirkness; Daniel C Payne; Kathryn M Edwards; James D Chappell; John T Patton
Journal:  J Virol       Date:  2012-06-13       Impact factor: 5.103

Review 5.  Rotavirus immune responses and correlates of protection.

Authors:  Juana Angel; Manuel A Franco; Harry B Greenberg
Journal:  Curr Opin Virol       Date:  2012-06-05       Impact factor: 7.090

6.  Treatment and prevention of rotavirus infection in children.

Authors:  Penelope H Dennehy
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

7.  Long-term variation in influenza A virus prevalence and subtype diversity in migratory mallards in northern Europe.

Authors:  Neus Latorre-Margalef; Conny Tolf; Vladimir Grosbois; Alexis Avril; Daniel Bengtsson; Michelle Wille; Albert D M E Osterhaus; Ron A M Fouchier; Björn Olsen; Jonas Waldenström
Journal:  Proc Biol Sci       Date:  2014-02-26       Impact factor: 5.349

8.  Molecular epidemiology of contemporary G2P[4] human rotaviruses cocirculating in a single U.S. community: footprints of a globally transitioning genotype.

Authors:  Allison F Dennis; Sarah M McDonald; Daniel C Payne; Slavica Mijatovic-Rustempasic; Mathew D Esona; Kathryn M Edwards; James D Chappell; John T Patton
Journal:  J Virol       Date:  2014-01-15       Impact factor: 5.103

9.  HIV population-level adaptation can rapidly diminish the impact of a partially effective vaccine.

Authors:  Joshua T Herbeck; Kathryn Peebles; Paul T Edlefsen; Morgane Rolland; James T Murphy; Geoffrey S Gottlieb; Neil Abernethy; James I Mullins; John E Mittler; Steven M Goodreau
Journal:  Vaccine       Date:  2017-12-11       Impact factor: 3.641

Review 10.  A critical literature review of health economic evaluations of rotavirus vaccination.

Authors:  Samuel Aballéa; Aurélie Millier; Sibilia Quilici; Stuart Caroll; Stavros Petrou; Mondher Toumi
Journal:  Hum Vaccin Immunother       Date:  2013-04-09       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.